French pharmacies 2026: market, taxation, structure and transmission — the owner's pillar guide

The French pharmacy of officine sector is at an inflection point in 2026. Network consolidation, the structural reform of professional practice companies (ordonnance 2023-77), the rise of new health missions (vaccination, pharmaceutical interviews, shared care plans, telecare), accelerated digitalisation (e-prescription, FMD serialisation, pharmaceutical record), and a transformed economic model (dispensing fees, ROSP) are reshaping reference points for practising owners and future buyers alike.

This pillar guide offers a deliberately panoramic view, written for a demanding audience: pharmacy owners, partner spouses, heirs, recent graduates considering installation, advisors, bankers and SPFPL investors. It anchors two complementary resources: our complete pharmacy & officine accountant guide, focused on operating an active pharmacy, and our pharmacy installation and acquisition 2026 guide, focused on the future owner's journey.

The objective here is to integrate four dimensions that are too often treated separately, although inseparable: the market, the taxation, the legal structure and the transmission. Without this integrated view, today's operational choices may compromise tomorrow's transmission.

Key idea: this panoramic guide does not replace personalised advice. It provides the framework. Every operational decision must be analysed with a specialised pharmacy accountant and a corporate / business lawyer.

1.1 Network status and demographics#

The metropolitan French pharmacy network stands at around 20,000 officines in 2026, vs over 22,000 in 2018. The decline is steady (≈ 1 %/year) and results from three dynamics:

• Mergers: two or three officines combine to reach critical size.
• Closures without buyer: especially in deeply under-served rural areas.
• Quota effect: no new pharmacy can open without meeting the population thresholds set by the Public Health Code.

This consolidation is not neutral: it lifts values in dynamic areas, weakens declining ones, and creates a structural deal flow linked to owner demographics (≈ 30 % older than 60).

1.2 Pharmacy revenue structure#

Dispensing fees introduced gradually since 2017, and the new public health missions, have transformed pharmacy income statements. Their share has doubled in five years and continues to grow — a more stable margin lever than regulated drug margins.

1.3 The role of buying groups#

Pharmaceutical buying groups (LDP, Leadersanté, Pharmavie, Giropharm, Welcoop, etc.) federate the vast majority of officines in 2026. They negotiate purchasing terms with labs, deliver mutualised digital tools and structure part of the commercial strategy. Membership influences gross margin (1 to 2.5 points), valuation (slight premium for well-integrated pharmacies) and the owner's strategic autonomy.

1.4 Competitive landscape and model evolution#

The competitive landscape is evolving: rise of online parapharmacy platforms, intra-network consolidation, growth of health advisory. But the pharmaceutical monopoly on prescription drugs, secured dispensing and proximity continue to structurally protect the model.

Key idea: in 2026, a French pharmacy remains a rare and resilient asset — but its profitability depends increasingly on diversification, management quality and digital mastery.

2.1 Pharmaceutical monopoly#

The pharmaceutical monopoly (article L.4211-1 Public Health Code) grants pharmacies the exclusive right to dispense human-use medicines. It underpins the goodwill's economic value — and imposes a strict deontological framework, supervised by the Ordre national des pharmaciens and the ARS.

2.2 Quotas and ARS authorisations#

Every pharmacy transfer, merger or creation requires ARS authorisation (article L.5125-3 et seq. CSP): creation prohibited unless population threshold is met (≥ 2,500 inhabitants for the first pharmacy, +4,500 per additional pharmacy); transfers possible to areas identified as priority; mergers encouraged under continuity of service. A change of owner does not generate a new operating right: the licence is attached to the location.

2.3 Professional independence and exclusivity of practice#

The owner pharmacist must operate the pharmacy personally. Exclusivity of practice — a single principal place — limits multiple ownership without a dedicated structure. The SPFPL, validated by the 2023 ordonnance, allows holding multiple pharmacist SELs (up to 4) within the deontological framework.

2.4 Compliance obligations 2026#

Key idea: technical and deontological compliance is not paperwork — it is a pharmacy asset that directly drives goodwill value at transmission.

3.1 Pharmacy VAT: daily complexity#

A pharmacy applies four VAT rates simultaneously, making it one of the most complex sectors. Our VAT calculator helps validate monthly returns on simple cases.

Common errors: miscalibrated LGO settings, ROSP declaration, VAT on magistral preparations. A parameterisation audit every 18 months is recommended.

3.2 Profit taxation#

The SEL at IS + SPFPL holding combination allows in 2026 to reinvest most profits at a residual fiscal cost of 1.25 % to 5 %, depending on the regime activated.

3.3 Dividend taxation#

An efficient strategy combines dividend upstreaming to the SPFPL (near-exemption) with salary / dividend arbitration at owner level to limit the TNS impact on the excess portion.

3.4 Local taxes (CFE, CVAE)#

The pharmacy is liable for CFE (article 1447 CGI) and, above a certain revenue, for CVAE (in gradual extinction; residual 2026 rate). For a high-revenue pharmacy, CVAE can still represent several thousand euros per year.

3.5 Owner's social contributions#

Our director remuneration simulator compares these regimes against a target profit.

3.6 CAVP: pharmacist pension scheme#

The CAVP is the mandatory pension scheme for French pharmacists. It combines a base regime (aligned with the general regime), a points-based supplementary regime, and a capitalisation supplementary regime. Total 2026 contribution for a SELARL owner generally reaches 12 to 18 % of remuneration with caps.

Key idea: the CAVP offers one of the best contribution / pension ratios among French liberal professions, justifying a strategy of maximising voluntary contributions (buybacks, optional classes).

4.1 EI, SELARL, SELAS: practice choices#

The EI (sole proprietor) remains possible but marginal in 2026. SELARL is still the dominant structure. SELAS is rising, especially for multi-partner setups and dividend-driven strategies. Our installation guide details the SELARL vs SELAS decision matrix.

4.2 SPFPL: structural lever#

The SPFPL has become, since the 2023 ordonnance, the central tool of pharmacist patrimonial structuring: ownership up to 100 % of a SEL, up to 4 pharmacy SELs held, acquisition debt carry, mother-daughter and tax consolidation regimes, transmission preparation (Pacte Dutreil, donation-partage). It follows a logic similar to a classical patrimonial holding, with specifics tied to the regulated profession. Our holding vs SCI guide explores the patrimonial trade-offs.

4.3 The SCI for the property: complementary patrimonial tool#

When the pharmacy property belongs to the pharmacist, owning it via a separate SCI (real estate civil company) enables to distinguish goodwill from real estate (often transmissible separately with more favourable taxation), to create a stable post-disposal rental income, and to optimise transmission via dismemberment. SCI under personal income tax vs SCI under IS depends on the holding horizon and overall patrimonial strategy.

4.4 Structures recap#

5.1 Transmission paths#

5.2 The Pacte Dutreil for pharmacists (article 787 B CGI)#

The Pacte Dutreil is the central tool for family pharmacy transmission. It allows a 75 % exemption on transmitted shares (donation or succession) under conditions: collective holding commitment (≥ 2 years) by the owner and at least one other partner or SPFPL holding; individual holding commitment (≥ 4 years) by the recipient; management function by one of the recipients for 3 years post-transmission; eligible activity (the pharmacist is eligible).

Illustrative example:

• Transmitted SELARL value: EUR 1,500,000
• Pacte Dutreil 75 % rebate: EUR 1,125,000
• Taxable base after Dutreil: EUR 375,000
• Parent-child allowance (EUR 100,000 per parent / per child): variable
• Tax saving: potentially several hundred thousand euros, to confirm by simulation.

Our complete Pacte Dutreil guide details the full mechanics, including SPFPL setups.

5.3 Donation-partage#

The donation-partage (articles 1075 et seq. Civil Code) lets the owner allocate among several children the pharmacy or SPFPL value with freezing of values at the gift date: a strong asset to neutralise future challenges and stabilise transmission. It combines with the Pacte Dutreil. Our donation-partage guide details the validity conditions.

5.4 Dismemberment and temporary usufruct sale#

Dismemberment of ownership (bare ownership to the successor, usufruct to the seller) enables anticipated transmission at reduced fiscal cost (the gift bears on bare ownership valued under article 669 CGI), preserves income for the seller via usufruct, and triggers automatic reunification of full ownership at death without further taxation.

Temporary usufruct sale (e.g. to a SPFPL for a fixed duration) is a sophisticated patrimonial tool — its rationale and risks are analysed in our dedicated guide.

5.5 Sale to a third party: seller's taxation#

The pharmacist selling the goodwill or SELARL shares is taxed on professional capital gain (article 39 duodecies CGI), with several exemption regimes: 151 septies (full exemption under revenue and 5-year holding conditions), 151 septies A (exemption on retirement within 24 months post-disposal), 238 quindecies (full exemption ≤ EUR 500,000 / partial ≤ EUR 1,000,000), apport-cession via SPFPL (article 150-0 B ter CGI deferral, under strict reinvestment conditions).

Key idea: disposal taxation is prepared 3 to 5 years before the operation. Any donation, restructuring or interim contribution poorly anticipated may forfeit a favourable regime.

5.6 The ideal transmission roadmap#

1. 5 to 10 years before: patrimonial structuring (SPFPL, SCI for property).
2. 3 to 5 years before: Pacte Dutreil collective commitment, possible bare ownership donation-partage.
3. 2 years before: full pharmacy audit, compliance, forecast valuation.
4. 6 to 12 months before: choice of mode (third-party sale, family transmission, mixed).
5. Year N: operation, post-disposal accompaniment.

6.1 FMD serialisation#

The serialisation of medicines required by EU Regulation 2016/161 transforms the dispensing chain. Pharmacies not yet equipped or technically lagging present a hidden upgrade cost of EUR 8,000 to 25,000, directly weighing on disposal valuation.

6.2 E-prescription and pharmaceutical record#

The 2026 generalisation of e-prescription changes dispensing flows and requires significant LGO updates. Equipped and trained pharmacies monetise their tech advance; others face operational and valuation risks.

6.3 Vaccination, interviews, shared care, TROD#

The new public health missions (flu/Covid/meningitis vaccination, pharmaceutical interviews, shared care plans, sore-throat and cystitis TROD) generate tariffed revenues unrelated to drug margin. In 2026, they represent 3 to 8 % of an active pharmacy's revenue — a margin lever to integrate in any business plan and valuation.

6.4 Dispensing fees#

Dispensing fees (complex prescription, elderly prescription, home dispensing) now form a significant and stable part of revenue. Their convention-based evolution must be tracked yearly and integrated in financial forecasts.

6.5 GDPR and cybersecurity#

Pharmacies process health data (special category under article 9 GDPR). Documented GDPR compliance (processing register, processor agreements, notices, individual rights handling) is a pharmacy asset — and in 2026 a systematic due diligence point for buyers and bankers.

6.6 Workforce: pharmacy collective agreement#

The pharmacy of officine collective agreement (IDCC 1996) frames classification, minimum salaries, bonuses and working conditions. Wage bill is 20 to 28 % of net revenue on average, with strong specifics: seniority bonus, level-based classification, on-call pay.

Our employer cost calculator simulates the total cost of a hire (preparator, associate, apprentice).

The 2026 sector rewards owners who think structure and transmission while operating. Three observations recur in our practice:

1. The best transmission operations are prepared 5 to 10 years before. At 60, many owners discover they have not put in place the building blocks (SPFPL, anticipated donation-partage, Pacte Dutreil) that would have saved several hundred thousand euros.

2. Pharmacy taxation cannot be siloed. Margin, VAT, IS, dividends, social contributions, transmission: everything is interconnected. A poorly calibrated salary-vs-dividend split penalises not only the current year but also long-term valuation and the Pacte Dutreil mechanics.

3. Technical compliance (serialisation, GDPR, e-prescription) has become a valuable asset. Well-documented pharmacies sell faster and better; lagging pharmacies face a discount.

Our conviction: every year, an owner pharmacist must do three things. Verify their fiscal and social arbitrations. Update their holding architecture (SPFPL, SCI for property). Move one notch on their transmission roadmap, even when it feels remote.

The no. 1 underestimated risk in 2026 is the disconnect between operating structure and transmission roadmap. Many owners have been advised on their SELARL or SELAS without integrating the transmission angle. Result: ineligible Pacte Dutreil due to a poorly drafted statutory clause; SPFPL set up too late (post collective commitment, forcing the chain to restart); apport-cession (article 150-0 B ter CGI) not anticipated, narrowing reinvestment options; donation-partage impossible because the heirs were not associated upstream.

These mistakes surface at the worst moment: at 65, when it is too late to rebuild the chain. The golden rule: every today's decision must be validated against tomorrow's transmission.

• SEL reform (ordonnance 2023-77): pre-2023 statutes must be audited — some clauses are void by law.
• Mother-daughter / tax consolidation: strict conditions (≥ 5 % holding for 2 years for mother-daughter; 95 % for consolidation). Any breach triggers retroactive loss of the benefit.
• Pacte Dutreil: collective commitment and management function are scrutinised. A breach generates a tax reassessment with surcharges.
• Apport-cession (150-0 B ter CGI): reinvestment obligation in an eligible activity — pharmacy and SEL are eligible under conditions.
• Pharmacy VAT: tax audits target LGO parameterisation and multi-rate consistency. A preventive audit every 18 months protects.
• Convention fees: track yearly evolutions (pharmaceutical convention amendments) and integrate in business plans.
• Cybersecurity and GDPR: a health data incident may trigger a significant CNIL sanction and a disposal discount.

• Yearly fiscal audit (VAT, IS, CFE, CVAE) with accountant
• Documented salary / dividend arbitration
• Beneficial owners register (RBE) updated at INPI
• Compliance review (ARS / Ordre / serialisation / GDPR)
• Patrimonial review with dedicated advisor
• Transmission roadmap progress review
• Statutes update (SEL / SPFPL / SCI) on regulatory evolution
• Insurance / Madelin / PER coverage check
• CAVP voluntary contributions and optional classes review
• Collective agreement and workforce classification review